$13.46
3.46%
Nasdaq, Apr 21, 08:48 pm CET
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Arcutis Biotherapeutics Inc Stock price

$13.01
-3.41 20.77% 1M
+3.52 37.09% 6M
-0.92 6.60% YTD
+2.76 26.93% 1Y
-7.09 35.27% 3Y
-14.27 52.31% 5Y
-8.79 40.32% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.05 0.39%
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Key metrics

Market capitalization $1.54b
Enterprise Value $1.43b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.25
P/S ratio (TTM) P/S ratio 7.85
P/B ratio (TTM) P/B ratio 9.73
Revenue growth (TTM) Revenue growth 229.74%
Revenue (TTM) Revenue $196.54m
EBIT (operating result TTM) EBIT $-128.40m
Free Cash Flow (TTM) Free Cash Flow $-112.30m
Cash position $228.57m
EPS (TTM) EPS $-1.16
P/E forward negative
P/S forward 4.99
EV/Sales forward 4.61
Short interest 15.21%
Show more

Is Arcutis Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Arcutis Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Arcutis Biotherapeutics Inc forecast:

Buy
100%

Financial data from Arcutis Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
197 197
230% 230%
100%
- Direct Costs 19 19
237% 237%
10%
177 177
229% 229%
90%
- Selling and Administrative Expenses 227 227
24% 24%
115%
- Research and Development Expense 76 76
31% 31%
39%
-126 -126
47% 47%
-64%
- Depreciation and Amortization 2.60 2.60
61% 61%
1%
EBIT (Operating Income) EBIT -128 -128
47% 47%
-65%
Net Profit -140 -140
47% 47%
-71%

In millions USD.

Don't miss a Thing! We will send you all news about Arcutis Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcutis Biotherapeutics Inc Stock News

Positive
Seeking Alpha
3 days ago
Arcutis Biotherapeutics is rated a buy with a $19 price target, driven by strong Zoryve sales, a solid balance sheet, and strategic CFO transition. CFO David Topper is stepping down, replaced by Latha Vairavan, whose expertise aligns better with Arcutis's current commercial stage and financial goals. Zoryve's performance exceeds expectations, with significant revenue growth and expanded Medicai...
Neutral
GlobeNewsWire
4 days ago
WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close.
Neutral
GlobeNewsWire
11 days ago
WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, Arcutis' chief financial officer (CFO) is retiring from the Company and Latha Vairavan, currently vice president and controller, will assume t...
More Arcutis Biotherapeutics Inc News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.

Head office United States
CEO Todd Watanabe
Employees 342
Founded 2016
Website www.arcutis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today